Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-01-18-Speech-2-504-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110118.20.2-504-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, the fight against Alzheimer’s disease has become a European priority in recent years and not before time! Let me add that I welcome all the initiatives that have just been announced by Commissioner Dalli.
This form of cerebral ageing is experiencing explosive growth in Europe and worldwide: more than 7 million people are affected, with this figure rising to 10 million if one considers other types of neurodegenerative illnesses. We can, and should, welcome the current EU funding of 32 research projects, but we must do better, much better, especially in terms of the coordination of research into Alzheimer’s in the Eighth Research Framework Programme as early as 2014. This is clearly specified in point 21 of our resolution.
It is also vital to focus on a multidisciplinary approach embracing diagnosis, prevention, treatment and support for the recipients of care and for their families; this is covered in points 2 and 20, which are very important. In this regard, moreover, a recent study, which has just been published in France, reveals the considerable socio-economic costs resulting from this disease: more than EUR 10 million a month for the medical care and supervision of patients alone. And that does not include the enormous dedication of the patients’ loved ones and families, who devote more than six hours a day to the care and management of the patient.
Helping these patients also means getting the diagnosis right. The scientific world tells us that international criteria must now be changed because, through the strict application of often obsolete criteria, too many patients who have other forms of dementia are often included.
At European level, which is covered by point 64 of our resolution, it is crucial that Parliament finally responds to the appeal from researchers. More volunteers are needed for the clinical studies if we hope to find a cure one day, which we must. The upcoming revision of the Clinical Trials Directive is therefore a golden opportunity to provide a concrete response and to give hope to the families affected."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples